Department of Clinical Sciences, Otorhinolaryngology, Umeå University, Östersund, Sweden.
Department of Clinical Sciences, Otorhinolaryngology, Umeå University, Umeå, Sweden.
Acta Otolaryngol. 2024 Jan;144(1):71-75. doi: 10.1080/00016489.2024.2316264. Epub 2024 Mar 4.
Recurrent respiratory papillomatosis (RRP) is a wart-like lesion mainly affecting the larynx, caused by human papillomavirus (HPV) genotypes 6 and 11. The disease affects both children and adults, and there is no cure. Surgery is the current symptom-relieving treatment; however, HPV vaccination is used as an adjuvant treatment.
The aims were to study effects of HPV vaccination in RRP cases and to compare juvenile-onset to adult-onset disease and high treatment frequency (TF) to low TF cases.
Medical records of RRP patients were studied from May 2006 to January 2023. Eighty-five RRP cases, tested for HPV genotypes with PapilloCheck®, were included. Vaccination- onset- and treatment analysis were performed.
Twelve percent of the cases were vaccinated. The number of surgeries decreased from 2.0 to 0.8/year after HPV vaccination. Most cases had an adult-onset and less than one treatment per year. Juvenile-onset cases had a higher vaccination treatment ratio compared to adult-onset.
HPV vaccination was associated with a lower number of treatments per year, supporting the use of vaccination as an adjuvant treatment.
Vaccination as adjuvant treatment to surgery may lead to increased quality of life for RRP patients and saved healthcare resources.
复发性呼吸道乳头瘤病（RRP）是一种疣状病变，主要影响喉部，由人乳头瘤病毒（HPV）基因型 6 和 11 引起。该疾病影响儿童和成人，目前尚无治愈方法。手术是目前缓解症状的治疗方法；然而，HPV 疫苗接种被用作辅助治疗。
本研究旨在研究 HPV 疫苗接种对 RRP 病例的影响，并比较青少年发病与成人发病以及高治疗频率（TF）与低 TF 病例。
研究了 2006 年 5 月至 2023 年 1 月期间 RRP 患者的病历。对 85 例经 PapilloCheck®检测 HPV 基因型的 RRP 病例进行了检测。进行了疫苗接种起始和治疗分析。
12%的病例接受了疫苗接种。HPV 疫苗接种后，手术数量从每年 2.0 次减少到 0.8 次/年。大多数病例发病年龄为成人，每年治疗次数少于一次。青少年发病的病例与成人发病相比，接种治疗比例更高。
HPV 疫苗接种与每年治疗次数减少相关，支持将疫苗接种作为辅助治疗。
手术辅助 HPV 疫苗接种可能会提高 RRP 患者的生活质量并节省医疗保健资源。
